- Join Longevity
- Archive
- Page 2
Archive
Major Setback for BioAge
In a dramatic turn of events that sent shockwaves through the biotech industry, BioAge Labs has faced a severe setback as their promising obesity treatment hits a critical roadblock. The company's stock plummeted by 80% after safety concerns forced the termination of a pivotal Phase 2 trial for azelaprag, their innovative weight-loss drug. This devastating market reaction has raised pressing questions about the future of both the company and its ambitious approach to obesity treatment.
Safety Considerations in Gene Therapy: Lessons from Recent Clinical Trial Events
Gene therapies represent one of the most promising avenues for developing truly impactful medical interventions and are poised to play a significant role in the longevity field. These innovative treatments offer the potential to address previously untreatable genetic conditions at their root cause. However, recent events serve as a crucial reminder of why rigorous clinical trials and safety protocols are essential.
Reframing Aging: The World Bank's Vision for Healthy Longevity
In a groundbreaking report, the World Bank has shifted the narrative around aging populations from a looming challenge to a promising opportunity. Titled "Unlocking the Power of Healthy Longevity," the report emphasizes the potential for advanced biomedicine and strategic health investments to transform demographic shifts into economic and social gains.
